Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer

Kunihiro Tsuchida, Masashi Nakatani, Akiyoshi Uezumi, Tatsuya Murakami, Xueling Cui

Research output: Contribution to journalReview article

128 Citations (Scopus)

Abstract

Activin, myostatin and other members of the TGF-β superfamily signal through a combination of type II and type I receptors, both of which are transmembrane serine/threonine kinases. Activin type II receptors, ActRIIA and ActRIIB, are primary ligand binding receptors for activins, nodal, myostatin and GDF11. ActRIIs also bind a subset of bone morphogenetic proteins (BMPs). Type I receptors that form complexes with ActRIIs are dependent on ligands. In the case of activins and nodal, activin receptor-like kinases 4 and 7 (ALK4 and ALK7) are the authentic type I receptors. Myostatin and GDF11 utilize ALK5, although ALK4 could also be activated by these growth factors. ALK4, 5 and 7 are structurally and functionally similar and activate receptor-regulated Smads for TGF-β, Smad2 and 3. BMPs signal through a combination of three type II receptors, BMPRII, ActRIIA, and ActRIIB and four type I receptors, ALK1, 2, 3, and 6. BMPs activate BMP-specific Smads, Smad1, 5 and 8. Smad proteins undergo multimerization with co-mediator Smad, Smad4, and translocated into the nucleus to regulate the transcription of target genes in cooperation with nuclear cofactors. The signal transduction pathway through activin type II receptors, ActRIIA and ActRIIB, with type I receptors is involved in various human diseases. In this review, we discuss the role of signaling through activin receptors as therapeutic targets of intractable neuromuscular diseases, endocrine disorders and cancers.

Original languageEnglish
Pages (from-to)11-21
Number of pages11
JournalEndocrine Journal
Volume55
Issue number1
DOIs
Publication statusPublished - 18-04-2008

Fingerprint

Activin Receptors
Musculoskeletal Diseases
Bone Morphogenetic Proteins
Myostatin
Signal Transduction
Type II Activin Receptors
Activins
Neoplasms
Endocrine Gland Neoplasms
Protein Multimerization
Smad Proteins
Ligands
Neuromuscular Diseases
Protein-Serine-Threonine Kinases
Therapeutics
Intercellular Signaling Peptides and Proteins
Genes

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{725b4082ecd84a64805ca5d90c2f330c,
title = "Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer",
abstract = "Activin, myostatin and other members of the TGF-β superfamily signal through a combination of type II and type I receptors, both of which are transmembrane serine/threonine kinases. Activin type II receptors, ActRIIA and ActRIIB, are primary ligand binding receptors for activins, nodal, myostatin and GDF11. ActRIIs also bind a subset of bone morphogenetic proteins (BMPs). Type I receptors that form complexes with ActRIIs are dependent on ligands. In the case of activins and nodal, activin receptor-like kinases 4 and 7 (ALK4 and ALK7) are the authentic type I receptors. Myostatin and GDF11 utilize ALK5, although ALK4 could also be activated by these growth factors. ALK4, 5 and 7 are structurally and functionally similar and activate receptor-regulated Smads for TGF-β, Smad2 and 3. BMPs signal through a combination of three type II receptors, BMPRII, ActRIIA, and ActRIIB and four type I receptors, ALK1, 2, 3, and 6. BMPs activate BMP-specific Smads, Smad1, 5 and 8. Smad proteins undergo multimerization with co-mediator Smad, Smad4, and translocated into the nucleus to regulate the transcription of target genes in cooperation with nuclear cofactors. The signal transduction pathway through activin type II receptors, ActRIIA and ActRIIB, with type I receptors is involved in various human diseases. In this review, we discuss the role of signaling through activin receptors as therapeutic targets of intractable neuromuscular diseases, endocrine disorders and cancers.",
author = "Kunihiro Tsuchida and Masashi Nakatani and Akiyoshi Uezumi and Tatsuya Murakami and Xueling Cui",
year = "2008",
month = "4",
day = "18",
doi = "10.1507/endocrj.KR-110",
language = "English",
volume = "55",
pages = "11--21",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "1",

}

Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. / Tsuchida, Kunihiro; Nakatani, Masashi; Uezumi, Akiyoshi; Murakami, Tatsuya; Cui, Xueling.

In: Endocrine Journal, Vol. 55, No. 1, 18.04.2008, p. 11-21.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer

AU - Tsuchida, Kunihiro

AU - Nakatani, Masashi

AU - Uezumi, Akiyoshi

AU - Murakami, Tatsuya

AU - Cui, Xueling

PY - 2008/4/18

Y1 - 2008/4/18

N2 - Activin, myostatin and other members of the TGF-β superfamily signal through a combination of type II and type I receptors, both of which are transmembrane serine/threonine kinases. Activin type II receptors, ActRIIA and ActRIIB, are primary ligand binding receptors for activins, nodal, myostatin and GDF11. ActRIIs also bind a subset of bone morphogenetic proteins (BMPs). Type I receptors that form complexes with ActRIIs are dependent on ligands. In the case of activins and nodal, activin receptor-like kinases 4 and 7 (ALK4 and ALK7) are the authentic type I receptors. Myostatin and GDF11 utilize ALK5, although ALK4 could also be activated by these growth factors. ALK4, 5 and 7 are structurally and functionally similar and activate receptor-regulated Smads for TGF-β, Smad2 and 3. BMPs signal through a combination of three type II receptors, BMPRII, ActRIIA, and ActRIIB and four type I receptors, ALK1, 2, 3, and 6. BMPs activate BMP-specific Smads, Smad1, 5 and 8. Smad proteins undergo multimerization with co-mediator Smad, Smad4, and translocated into the nucleus to regulate the transcription of target genes in cooperation with nuclear cofactors. The signal transduction pathway through activin type II receptors, ActRIIA and ActRIIB, with type I receptors is involved in various human diseases. In this review, we discuss the role of signaling through activin receptors as therapeutic targets of intractable neuromuscular diseases, endocrine disorders and cancers.

AB - Activin, myostatin and other members of the TGF-β superfamily signal through a combination of type II and type I receptors, both of which are transmembrane serine/threonine kinases. Activin type II receptors, ActRIIA and ActRIIB, are primary ligand binding receptors for activins, nodal, myostatin and GDF11. ActRIIs also bind a subset of bone morphogenetic proteins (BMPs). Type I receptors that form complexes with ActRIIs are dependent on ligands. In the case of activins and nodal, activin receptor-like kinases 4 and 7 (ALK4 and ALK7) are the authentic type I receptors. Myostatin and GDF11 utilize ALK5, although ALK4 could also be activated by these growth factors. ALK4, 5 and 7 are structurally and functionally similar and activate receptor-regulated Smads for TGF-β, Smad2 and 3. BMPs signal through a combination of three type II receptors, BMPRII, ActRIIA, and ActRIIB and four type I receptors, ALK1, 2, 3, and 6. BMPs activate BMP-specific Smads, Smad1, 5 and 8. Smad proteins undergo multimerization with co-mediator Smad, Smad4, and translocated into the nucleus to regulate the transcription of target genes in cooperation with nuclear cofactors. The signal transduction pathway through activin type II receptors, ActRIIA and ActRIIB, with type I receptors is involved in various human diseases. In this review, we discuss the role of signaling through activin receptors as therapeutic targets of intractable neuromuscular diseases, endocrine disorders and cancers.

UR - http://www.scopus.com/inward/record.url?scp=42049114841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049114841&partnerID=8YFLogxK

U2 - 10.1507/endocrj.KR-110

DO - 10.1507/endocrj.KR-110

M3 - Review article

C2 - 17878607

AN - SCOPUS:42049114841

VL - 55

SP - 11

EP - 21

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 1

ER -